Provided is a method for industrially advantageously producing a fluorinated hydrocarbon (3). The disclosed method for producing a fluorinated hydrocarbon represented by formula (3) includes bringing into contact, in a hydrocarbon-based solvent, a secondary or tertiary ether compound represented by formula (1) below with an acid fluoride represented by formula (2) in the presence of lithium salt or sodium salt (in the formulae, R.sup.1 and R.sup.2 each represent a C.sub.1-3 alkyl, and R.sup.1 and R.sup.2 may be bonded to each other to form a ring structure; R.sup.3 represents a hydrogen atom, methyl, or ethyl; and R.sup.4 and R.sup.5 each represent methyl or ethyl). ##STR00001##

Provided is a method for industrially advantageously producing a fluorinated hydrocarbon (3). The disclosed method for producing a fluorinated hydrocarbon represented by formula (3) includes bringing into contact, in a hydrocarbon-based solvent, a secondary or tertiary ether compound represented by formula (1) below with an acid fluoride represented by formula (2) in the presence of lithium salt or sodium salt (in the formulae, R.sup.1 and R.sup.2 each represent a C.sub.1-3 alkyl, and R.sup.1 and R.sup.2 may be bonded to each other to form a ring structure; R.sup.3 represents a hydrogen atom, methyl, or ethyl; and R.sup.4 and R.sup.5 each represent methyl or ethyl). ##STR00001##

Provided is a method for industrially advantageously producing a fluorinated hydrocarbon (3). The disclosed method for producing a fluorinated hydrocarbon represented by formula (3) includes bringing into contact, in a hydrocarbon-based solvent, a secondary or tertiary ether compound represented by formula (1) below with an acid fluoride represented by formula (2) in the presence of lithium salt or sodium salt (in the formulae, R.sup.1 and R.sup.2 each represent a C.sub.1-3 alkyl, and R.sup.1 and R.sup.2 may be bonded to each other to form a ring structure; R.sup.3 represents a hydrogen atom, methyl, or ethyl; and R.sup.4 and R.sup.5 each represent methyl or ethyl).

##STR00001##

Provided is a method for industrially advantageously producing a fluorinated hydrocarbon (3). The disclosed method for producing a fluorinated hydrocarbon represented by formula (3) includes bringing into contact, in a hydrocarbon-based solvent, a secondary or tertiary ether compound represented by formula (1) below with an acid fluoride represented by formula (2) in the presence of lithium salt or sodium salt (in the formulae, R.sup.1 and R.sup.2 each represent a C.sub.1-3 alkyl, and R.sup.1 and R.sup.2 may be bonded to each other to form a ring structure; R.sup.3 represents a hydrogen atom, methyl, or ethyl; and R.sup.4 and R.sup.5 each represent methyl or ethyl).

##STR00001##

The present invention provides 5-HT3 receptor antagonists of Formula (I): ##STR00001##
which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention provides 5-HT3 receptor antagonists of Formula (I): ##STR00001##
which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention provides 5-HT3 receptor antagonists of Formula (I):

##STR00001##

which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention provides 5-HT3 receptor antagonists of Formula (I):

##STR00001##

which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention provides 5-HT3 receptor antagonists of Formula (I): ##STR00001##
which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention provides 5-HT3 receptor antagonists of Formula (I): ##STR00001##
which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.